Disclosures Drs Khan, Naegeli, and Viktrup are fulltime employees and hold stocks and/or stock options with Eli Lilly and Company. Eli Lilly and Company is investigating new pharmaceutical therapies for the treatment of BPH-LUTS.
Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient
Version of Record online: 17 AUG 2012
© 2012 Blackwell Publishing Ltd
International Journal of Clinical Practice
Volume 66, Issue 9, pages 883–890, September 2012
How to Cite
Kingery, L., Martin, M. L., Naegeli, A. N., Khan, S. and Viktrup, L. (2012), Content validity of the Benign Prostatic Hyperplasia Impact Index (BII); a measure of how urinary trouble and problems associated with BPH may impact the patient. International Journal of Clinical Practice, 66: 883–890. doi: 10.1111/j.1742-1241.2012.02960.x
- Issue online: 17 AUG 2012
- Version of Record online: 17 AUG 2012
- Paper received October 2011, accepted April 2012
Aims: The objective of this qualitative interview study was to assess the content validity of the Benign Prostatic Hyperplasia Impact Index (BII) in a sample of men with signs and symptoms of Benign Prostatic Obstruction believed to be caused by benign prostatic hyperplasia (BPH lower urinary tract symptoms/BPH-LUTS) using concept elicitation (CE) and cognitive interviewing (CI) methods.
Methods: Fifty men with BPH-LUTS participated in the study; 27 completed CE interviews and 23 completed cognitive interviews.
Results: Patient’s average age was 69 years with a mean duration of BPH-LUTS of 6.5 years. IPSS scores ranged from 8 to 33 (higher scores indicating greater symptom severity). Overall, the most frequent symptoms (prevalence of ≥ 75%) reported spontaneously or after further explanation were awakening from sleep, increased daytime voiding (frequency), urgent desire to void (urgency), slow stream, and feeling of incomplete bladder emptying. Symptoms primarily recognized in response to follow up probe questions with a prevalence of ≥ 40% included terminal dribble, splitting of urinary stream, intermittent stream, straining and post-micturition dribble. Especially bothersome [> 5 on the numerical rating scale (NRS) of 0–10] and frequent symptoms included urgency and awakening at night to void. Discomfort or pain while urinating and post-micturition dribble were equally bothersome though less frequent. Five BPH symptom-related impact themes were identified: coping, daily responsibilities, emotion, lifestyle and relationships, and sleep.
Conclusions: The BII was found to be easily understood, does capture clinically relevant BPH impacts related to urinary trouble and problems, and does capture most of the important symptom-related impacts as described by participants in this study.